B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Olema Pharmaceuticals, Inc. - Common Stock (NQ:OLMA)

11.48 +0.95 (+9.02%)
Streaming Delayed Price Updated: 12:49 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Olema Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Clinical Trial Collaboration and Supply Agreement with Bayer to Evaluate OP-3136 in Combination with NUBEQA® (darolutamide) in Metastatic Castration-Resistant Prostate Cancer
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Appoints Prakash Raman, Ph.D., to Board of Directors
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Initial Clinical Data for OP-3136 at the 2026 ASCO Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Pharmaceuticals, Inc. Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – OLMA
From DJS Law Group
Via Business Wire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Departure of Chief Operating and Financial Officer
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present at 44th Annual J.P. Morgan Healthcare Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in 8th Annual Evercore Healthcare Conference
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Closing of $218.5 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Pricing of $190.0 Million Public Offering of Common Stock
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Participate in Upcoming Investor Conferences
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
From Olema Oncology
Via GlobeNewswire
News headline image
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
From Olema Oncology
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.